Summary of Key Points from the Conference Call Industry Overview - The report covers the pharmaceutical industry in China, with specific focus on stock performance and company announcements within the sector. Market Performance - The Shanghai Composite Index closed at 4114.00 points, with an increase of 0.29% [1] - The Shenzhen Component Index closed at 14294.05 points, with an increase of 0.09% [1] - The ChiNext Index closed at 3337.61 points, showing a decrease of 0.70% [1] - The Shenwan Pharmaceutical Industry Index closed at 8732.25 points, reflecting a decrease of 0.80% [1] - The Hang Seng Healthcare Index in Hong Kong closed at 4094.97 points, with a decline of 2.81% [1] Top Gainers and Losers in A-Shares - Top three gainers: - Sunflower (19.90%) [1] - Wanzhe Co. (10.02%) [1] - Tianmu Pharmaceutical (9.99%) [1] - Top three losers: - Luyuan Pharmaceutical (-10.01%) [1] - Zhifei Biological (-7.19%) [1] - Shanghai Yizhong (-6.88%) [1] Company Announcements - **Tianjin Pharmaceutical**: Vice General Manager Chen Hong has resigned [1] - **Eddie Pharmaceutical**: ADC205 tablets have received clinical trial approval [2] - **Mingde Biological**: Plans to increase capital and acquire 51% stake in Hunan Lanyi, aiming to build a collaborative ecosystem for critical and chronic disease management [1] - **Lanfang Medical**: Subsidiary Lithonic's intravascular shockwave treatment system has obtained CE certification [1] - **Ruimaite**: The company forecasts a net profit attributable to shareholders for 2025 between 190 million to 235 million yuan, representing a year-on-year growth of 22.28% to 51.24%. The net profit after deducting non-recurring gains and losses is expected to be between 128.5 million to 164 million yuan, with a growth of 38.97% to 77.37%. Revenue is projected to reach between 1.08 billion to 1.2 billion yuan, compared to 843.48 million yuan in the previous year [1]

Economic Overview - The GDP growth for Q4 2025 is reported at 4.5%, matching expectations but down from 4.8% in the previous quarter. December retail sales growth is at 0.9%, below the expected 1.5% and previous 1.3% [12][12] - Fixed asset investment shows a cumulative year-on-year decline of 3.8%, worse than the expected decline of 2.4% and previous 2.6%. Real estate development investment has a cumulative decline of 17.2% compared to the previous 15.9% [12][12] - Industrial value-added growth for December is reported at 5.2%, exceeding the expected 4.9% and previous 4.8% [12][12] Key Changes in Economic Structure - Three significant changes are identified: improvement in service consumption, easing of the "crowding out effect" from debt reduction, and recovery in new economic sectors [12][12] - The shift in consumption policies from goods to services is noted, with service retail growth increasing while traditional retail indicators decline [12][12] - Investment slowdown is attributed to intensified corporate debt repayment policies, which ultimately benefit cash flow recovery for companies [12][12] Sector Performance - The electric grid equipment sector shows a significant increase of 60.88% over the past six months, with a daily increase of 7.01% [1] - The digital media sector has seen a decline of 4.34% yesterday, with a 21.93% increase over the past month [1] - The hotel and catering industry has increased by 3.87% yesterday and 20.46% over the past six months, indicating resilience in service consumption [1] Investment Opportunities - The report highlights potential investment opportunities in sectors benefiting from service consumption recovery and easing debt repayment pressures [12][12] - Companies in the PCB drilling needle industry are noted for their growth potential, driven by increasing demand in emerging markets [20][20] - The report suggests focusing on companies with strong cash flow recovery and those positioned in high-growth sectors such as healthcare and technology [12][12][20]

Core Viewpoint - The company, Bluestar Medical Co., Ltd., has received EU CE certification for its LithonicTM Coronary Intravascular Lithotripsy system, marking a significant advancement in the treatment of calcified lesions in coronary arteries [1][2]. Group 1: Product Information - Product Name: LithonicTM Coronary Intravascular Lithotripsy (IVL) Catheter / Generator [1] - Manufacturer: Biosensors Interventional Technologies Pte. Ltd. (Singapore) [1] - Validity Period: Until January 13, 2031 [1]. Group 2: Product Description - The LithonicTM system utilizes high-pressure sound waves to treat severely calcified narrow areas in blood vessels, particularly where balloon dilation or stent expansion is ineffective [1]. - The system operates on the principle of electrolysis in an electrolyte solution, allowing precise release of high-pressure shock waves to modify calcified lesions and reduce complications associated with traditional treatment methods [1]. Group 3: Impact on the Company - The IVL technology is emerging as a preferred clinical option for treating calcified lesions due to its unique mechanism of action [2]. - The CE certification enhances the company's technological leadership in the coronary field and is expected to positively impact the company's operational development and overall competitiveness in the cardiovascular sector [2].

Core Viewpoint - The announcement highlights that the LithonicTM Coronary Intravascular Lithotripsy system has received CE certification, marking a significant advancement for the company in the cardiovascular treatment sector [1][2]. Product Information - The product, LithonicTM Coronary Intravascular Lithotripsy (IVL) Catheter / Generator, is manufactured by Biosensors Interventional Technologies Pte. Ltd. in Singapore and is valid until January 13, 2031 [1]. - The system is designed to treat severely calcified narrow areas in blood vessels by releasing high-pressure sound waves, which helps to modify calcified lesions and reduce the risk of complications associated with traditional treatment methods [1]. Impact on the Company - The CE certification of the LithonicTM system signifies international recognition of its clinical efficacy and safety, enhancing the company's competitive edge in the coronary field [2]. - The innovative IVL technology is becoming a preferred clinical option for treating calcified lesions, which is expected to positively influence the company's operational development [2].

Core Viewpoint - Mingde Bio has signed an acquisition agreement to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. for 35.71 million yuan, marking its entry into chronic disease management while continuing its focus on critical care diagnostics [2][10]. Acquisition Details - The acquisition involves a cash payment of 35.71 million yuan, with a phased approach and multiple performance guarantees to mitigate the risk of losses from the acquisition target [3][9]. - After the first phase of the acquisition, Hunan Lanyi will become a subsidiary of Mingde Bio, with the shareholding structure being Mingde Bio (51%), Lanyi Technology Group (29%), and Jiashan Hexin Consulting (20%) [4]. Financial Performance of Hunan Lanyi - Hunan Lanyi, established in September 2020, focuses on IVD instruments and reagents, particularly in glycated hemoglobin testing, but is currently operating at a loss due to high initial R&D and market expansion costs [6][10]. - Financial data indicates that Hunan Lanyi is projected to have a net loss of 20.68 million yuan in 2024 and has already incurred a loss of 23.98 million yuan in the first three quarters of 2025, exceeding the total loss for 2024 [6][7]. Performance Guarantees and Conditions - The acquisition agreement includes performance conditions where if Hunan Lanyi achieves an average net profit of at least 20 million yuan from 2026 to 2028, Mingde Bio will proceed with the second phase of the acquisition at a valuation of up to 504 million yuan [9]. - Additional clauses include adjustments to the valuation if Hunan Lanyi's revenue falls below 50 million yuan in 2025, and compensation requirements if certain profit thresholds are not met in subsequent years [9]. Strategic Intent - This acquisition is part of Mingde Bio's strategy to expand its business model from critical care to chronic disease management, aiming to create a comprehensive service ecosystem that covers pre-hospital emergency care, in-hospital diagnostics, and post-discharge management [10][11]. - The company emphasizes that the acquisition will enhance its service capabilities and open new market opportunities, particularly in both domestic and international markets [11].

Investment Rating - The industry investment rating is "Overweight" indicating a positive outlook for the high-value medical consumables sector [1]. Core Insights - The sixth batch of national centralized procurement for high-value medical consumables was held on January 13, 2026, with 12 types of medical consumables included, resulting in 440 products from 202 companies being selected [1]. - The selection rules were optimized to ensure that clinically recognized and capable products were chosen, emphasizing a "de-involution" approach [2]. - The report highlights the long-term growth potential of the high-value consumables sector post-price reduction expectations, driven by an aging population and increasing surgical and diagnostic volumes [2]. Summary by Sections Procurement Results - The procurement included drug-coated balloons and urological intervention consumables, with a high selection rate: all 42 products from 32 companies in the drug-coated balloon category were selected, and 398 products from 170 companies in the urological intervention category were chosen [2]. - Specific products with unique functions were also selected, meeting clinical needs [2]. Selection Rules - The selection process ensured that products with high clinical recognition and strong supply capabilities were prioritized [2]. - A pricing mechanism was introduced to reflect clinical value, avoiding a simple lowest-price selection method [2]. Company Analysis - Key companies involved include Lepu Medical, MicroPort Medical, and others, with notable price reductions in selected products compared to previous procurements [2]. - The report suggests monitoring companies such as Lepu Medical, MicroPort Medical, and others for investment opportunities [2]. Valuation Table - A valuation table is provided, showing market capitalization and projected profits for various companies, indicating their financial performance and P/E ratios for 2026 and 2027 [3].

Core Viewpoint - The company, Bluestar Medical (002382.SZ), announced that its subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received CE certification for the Lithonic coronary intravascular shockwave treatment system, which is designed to treat severely calcified stenosis areas [1][1]. Group 1 - The Lithonic system is intended for use in areas of severe calcification where balloon dilation or stent expansion is insufficient [1][1]. - The system operates by releasing high-pressure shockwaves to pre-treat calcified lesions, utilizing an electrolytic effect in a solution medium [1][1]. - The technology aims to directly modify calcified lesions and reduce the risk of complications associated with traditional treatment methods, such as vascular perforation and no-reflow phenomena [1][1].

Core Viewpoint - The company, Bluestar Medical (002382.SZ), announced that its subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received CE certification for the Lithonic™ coronary intravascular shockwave treatment system, which is designed to treat severely calcified narrow areas in blood vessels [1] Group 1 - The Lithonic™ system is intended for use in areas where balloon dilation is insufficient or stents cannot be evenly expanded due to calcification [1] - The system operates on the principle of utilizing electrodes in an electrolyte solution to generate high-pressure shockwaves, which are precisely delivered within the blood vessels to modify calcified lesions [1] - This innovative approach aims to reduce the risk of complications associated with traditional treatments for calcified lesions, such as vascular perforation and no-reflow phenomena [1]

Core Viewpoint - The company Bluepha Medical (002382.SZ) announced that its subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received CE certification for its Lithonic coronary intravascular shockwave treatment system, which is designed to treat severely calcified narrow areas in blood vessels [1] Group 1 - The Lithonic system is intended for use in areas where balloon dilation or stent expansion is insufficient due to calcification [1] - The system operates by releasing high-pressure shockwaves to pre-treat calcified lesions, utilizing an electrolytic effect generated by electrodes in an electrolyte solution [1] - This innovative approach aims to reduce the risk of complications such as vascular perforation and no-reflow associated with traditional calcification treatment methods [1]

Core Viewpoint - The company, Bluestar Medical (002382.SZ), announced that its subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received CE certification for the Lithonic™ coronary intravascular shockwave treatment system, which is designed to treat severely calcified narrow areas in blood vessels [1] Group 1 - The Lithonic™ system is intended for use in areas where balloon dilation is insufficient or stents cannot be evenly expanded due to calcification [1] - The system operates by releasing high-pressure shockwaves to pre-treat calcified lesions, utilizing the electrolysis effect in an electrolyte solution to precisely deliver the treatment [1] - This innovative approach aims to reduce the risk of complications associated with traditional calcified lesion treatments, such as vascular perforation and no-reflow phenomena [1]